Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published September 22, 2014 | Supplemental Material + In Press + Published
Journal Article Open

Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques

Abstract

It is widely appreciated that effective human vaccines directed against viral pathogens elicit neutralizing antibodies (NAbs). The passive transfer of anti–HIV-1 NAbs conferring sterilizing immunity to macaques has been used to determine the plasma neutralization titers, which must be present at the time of exposure, to prevent acquisition of SIV/HIV chimeric virus (SHIV) infections. We administered five recently isolated potent and broadly acting anti-HIV neutralizing monoclonal antibodies (mAbs) to rhesus macaques and challenged them intrarectally 24 h later with either of two different R5-tropic SHIVs. By combining the results obtained from 60 challenged animals, we determined that the protective neutralization titer in plasma preventing virus infection in 50% of the exposed monkeys was relatively modest (∼1:100) and potentially achievable by vaccination.

Additional Information

© 2014 Rockefeller University Press. Submitted: 2 December 2013. Accepted: 15 July 2014. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/). We thank Keiko Tomioka and Robin Kruthers for determining plasma viral RNA loads and Boris Skopets, William Magnanelli, and Rahel Petros for diligently assisting in the maintenance of animals and assisting with procedures. This work was supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health. The authors declare no competing financial interests.

Attached Files

Published - J_Exp_Med-2014-Shingai-2061-74.pdf

Supplemental Material - JEM_20132494_sm.pdf

In Press - J_Exp_Med-2014-Shingai-jem.20132494.pdf

Files

JEM_20132494_sm.pdf
Files (5.3 MB)
Name Size Download all
md5:05fb87ab92554e030b6579a8243e619a
452.2 kB Preview Download
md5:85aafeeca07e30b7051951b24288b72a
2.4 MB Preview Download
md5:aa32d049397fc18dfc0b20a7182d2437
2.4 MB Preview Download

Additional details

Created:
August 20, 2023
Modified:
October 17, 2023